JFDA (Jordan)

JFDA (the Jordan Food and Drug Administration) is the Hashemite Kingdom of Jordan's autonomous national regulatory authority responsible for the regulation of human medicines + biologicals + vaccines + medical devices + IVDs + cosmetics + food + dietary supplements + veterinary medicines + pharmacy practice + controlled substances. JFDA was established under Law 31 of 2003 + restructured by Law 41 of 2008 + amended through Law 12 of 2020, consolidating regulatory functions previously dispersed across the Ministry of Health Drug Directorate + the Ministry of Agriculture Food Directorate into a single autonomous agency reporting directly to the Prime Minister.

JFDA's organisational structure includes:

• Director General — chief executive appointed by Royal Decree on the recommendation of the Prime Minister; serves at the King's discretion.
• Board of Directors — governing board with multi-ministerial (Health, Agriculture, Industry, Trade, Finance) + scientific + civil-society representation; chaired by the Minister of Health.
• Drug Directorate — drug + biological + vaccine + biosimilar + generic-medicine registration via Marketing Authorisation procedure.
• Medical Devices Directorate — medical-device + IVD + reagent registration + post-market vigilance.
• Food Directorate — food + dietary supplement + nutraceutical registration + food-safety surveillance.
• Cosmetics Directorate — cosmetic-product notification + post-market cosmétovigilance.
• Veterinary Medicines Directorate — veterinary medicines + animal-feed additives registration (distinctive Jordanian model: veterinary medicines sit with JFDA, not with Ministry of Agriculture as in most Arab countries).
• Inspection Directorate — Jordanian + foreign manufacturer + distributor + pharmacy GMP/GDP/GPP/GVP/GLP inspections.
• Pharmacovigilance Directorate — Jordan National Pharmacovigilance Centre (JNPC, Amman) coordination + WHO PIDM coordination.
• Drug Pricing + Reimbursement Directorate — pharmaceutical-price regulation + reimbursement coordination with Royal Medical Services + Ministry of Health + Civil Insurance + UNRWA.
• International Affairs + Cooperation Directorate — international cooperation + WHO + EMA + GHC + Arab League + AMRH + ICH coordination.
• JFDA Central Laboratories (Shafa Badran, Amman) — central pharmaceutical + food + medical-device QC laboratory complex; ISO/IEC 17025 accredited + WHO PQ-Lab since 2011.
• JNPC (Jordan National Pharmacovigilance Centre, Amman) — integrated pharmacovigilance + matériovigilance + cosmétovigilance centre operating under JFDA coordination.
• Anti-Counterfeit + Smuggling Directorate — coordination with Jordan Customs + Public Security Directorate + Ministry of Interior for counterfeit-medicine enforcement.
• Network of regional inspectors coordinated through 12 Governorates (Amman, Irbid, Zarqa, Balqa, Madaba, Karak, Tafilah, Ma'an, Aqaba, Mafraq, Jerash, Ajloun).

JFDA is distinct from + complementary to: the Ministry of Health (MoH) broader Directorates (Primary Healthcare, Hospitals, Public Health); the Higher Health Council (national health-policy advisory body); the Jordan Pharmaceutical Association (JPA, pharmacist professional body); the Jordanian Pharmaceutical Manufacturers Association (JAPM, industry trade body); the Royal Medical Services (RMS, military + Royal Family healthcare with separate procurement); the Joint Procurement Department (JPD, public-sector pharmaceutical procurement coordinator); + the National Drug Information Centre. Jordan's institutional environment is characterised by: substantial domestic pharmaceutical manufacturing capacity (~25 manufacturers including Hikma Pharmaceuticals, Dar Al Dawa, Pharma International Company, Al-Hikma, Tabuk Pharmaceuticals Jordan); one of the highest pharmaceutical export ratios globally (~80% of domestic production exported to ~80 countries); a strong francophone-influenced + EU-aligned + US-influenced + Arab regulatory tradition reflecting Jordan's historical Hashemite + British Mandate + post-1946 independence multi-influence trajectory; + substantial refugee-population-driven public-health regulatory considerations (Jordan hosts substantial Syrian + Palestinian + Iraqi refugee populations through UNRWA + UNHCR coordination).

Legal foundations are Law 31 of 2003 (JFDA Establishment Law); Law 41 of 2008 + Law 12 of 2020 (JFDA Restructuring Laws); Drug + Pharmacy Law 12 of 2013 + amendments; Food Control Law 79 of 2001 + amendments; Medical Devices Bylaw 32 of 2014; Cosmetics Bylaw + JFDA Decisions; Narcotic Drugs + Psychotropic Substances Law 23 of 2016 (substantively aligned with UN Single Convention 1961 + Conventions 1971 + 1988); + a substantial body of JFDA Bylaws + Decisions + Guidance Documents. Jordanian pharmaceutical regulation operates substantively in Arabic (official language) with English (working language + scientific publication) labelling requirements.

JFDA achieved WHO Maturity Level 3 (ML3) for medicines in 2022 — one of the few Arab-region NRAs at ML3 alongside Saudi SFDA + Egypt EDA + Morocco DMP candidacy + Tunisia DPM/ANPM trajectory. JFDA is a WHO Listed Authority + an active WHO Prequalification Collaborative Registration Procedure (CRP) participating authority + a Gulf Health Council (GHC) coordination partner + a League of Arab States Council of Arab Ministers of Health pharmaceutical-harmonisation co-leader + an EMA Working Arrangement holder since 2018 + a PIC/S Pre-Accession Applicant + holds substantial cooperation arrangements with FDA + EMA + ANSM France + MHRA + Health Canada + TGA + Swissmedic + SFDA + UAE MoHAP + Egypt EDA + Morocco DMP + Tunisia DPM/ANPM + Algeria ANPP + Lebanon MoH + Iraq MoH + Palestinian MoH.

Jordanian pharmaceutical regulation operates under a layered framework of Laws + Bylaws + JFDA Decisions + Guidance Documents:

• Law 31 of 2003 — JFDA Establishment Law (founding law).
• Law 41 of 2008 + Law 12 of 2020 — JFDA Restructuring Laws.
• Drug + Pharmacy Law 12 of 2013 + amendments — drug + pharmacy practice framework.
• Food Control Law 79 of 2001 + amendments — food + dietary supplement framework.
• Medical Devices Bylaw 32 of 2014 — medical-device + IVD regulatory framework.
• Narcotic Drugs + Psychotropic Substances Law 23 of 2016 — controlled-substances framework substantively aligned with UN Single Convention 1961 + Conventions 1971 + 1988.
• Cosmetics Bylaw + JFDA Decisions — cosmetic-product notification framework substantively aligned with EU Cosmetics Regulation.
• JFDA GMP Guide — substantively aligned with PIC/S GMP Guide + EU GMP + ICH Q7 + WHO TRS 986 Annex 2.
• JFDA GDP Guide — substantively aligned with WHO + EU GDP.
• JFDA GCP Guide — substantively aligned with ICH E6(R2).
• JFDA GVP Guide — substantively aligned with ICH E2 + EU GVP.
• Jordanian Pharmacopoeia — recognises British Pharmacopoeia + USP + European Pharmacopoeia + Arab Pharmacopoeia.
• JFDA Medical Devices framework — Class I-III risk-based classification substantively aligned with EU MDR + GHTF/IMDRF + GCC-MD.
• JFDA Variations + 5-year Marketing Authorisation Renewal framework.
• Veterinary Medicines Bylaw — distinctive Jordanian model placing veterinary medicines under JFDA (not Ministry of Agriculture).

JFDA Central Laboratories is JFDA's central pharmaceutical + food + medical-device quality-control laboratory complex in Amman (Shafa Badran) + is ISO/IEC 17025 accredited (JAS — Jordan Accreditation System) + a WHO Prequalification of Quality Control Laboratories (WHO PQ-Lab) since 2011 — one of the earliest WHO PQ-Labs in the Arab World joining Egypt EDA NODCAR + Morocco LNCM + Tunisia LNCM + Saudi SFDA Central Laboratory as the WHO-prequalified pharmaceutical QC laboratory complex in the MENA region.

• ISO/IEC 17025 Accreditation — JFDA Central Laboratories is ISO/IEC 17025 accredited (JAS — Jordan Accreditation System) across multiple testing scopes including pharmaceutical chemical + microbiological + biological + food + medical-device testing.
• WHO PQ-Lab Designation Since 2011 — JFDA Central Laboratories is one of the earliest WHO PQ-Labs in the Arab World; supports WHO PQ + JFDA regulatory testing + Global Fund + Gavi + UNICEF procurement quality assurance.
• Arab League + AMRH Regional Reference Laboratory — JFDA Central Laboratories serves as Arab-region reference laboratory for selected pharmaceutical + food + medical-device categories.
• Vaccine lot release — JFDA Central Laboratories conducts vaccine lot-release testing for JFDA + Jordanian National Immunization Programme + selected MENA vaccine programmes.
• Pharmaceutical pre-registration + post-market testing — JFDA Central Laboratories conducts pre-registration quality testing + post-market surveillance + targeted enforcement testing for JFDA.
• Food + dietary-supplement testing — JFDA Central Laboratories conducts food + dietary-supplement pre-market + post-market quality + safety testing.
• Medical-device + IVD testing — JFDA Central Laboratories conducts medical-device + IVD pre-market + post-market quality testing.
• Cosmetic-product testing — JFDA Central Laboratories conducts cosmetic-product safety + ingredient compliance testing.
• Counterfeit-medicine forensics — JFDA Central Laboratories provides forensic analytical support for JFDA + Jordan Customs investigations + WHO Global Surveillance & Monitoring System contributions.
• Capacity-building — JFDA Central Laboratories hosts Arab League + GHC + AMRH + WHO capacity-building programmes + training for Arab-region pharmaceutical analysts.
• GMP Inspectorate support — JFDA Central Laboratories provides scientific + technical support for JFDA GMP inspections of Jordanian + foreign manufacturing facilities.
• Jordanian Pharmacopoeia development — JFDA Central Laboratories contributes to Arab Pharmacopoeia + Jordanian-specific monograph development alongside BP + USP + EP harmonisation.

JFDA medical-device + IVD regulation operates under Medical Devices Bylaw 32 of 2014 + JFDA Medical Devices framework with Class I-III risk-based classification substantively aligned with EU MDR + GHTF/IMDRF + GCC-MD. Foreign manufacturers must appoint a Jordanian Authorised Representative.

• Risk-based Classification (Class I / IIa / IIb / III) — substantively aligned with EU MDR + GHTF/IMDRF + GCC-MD; IVDs classified under separate Jordanian IVD framework.
• Jordanian Authorised Representative — Jordan-resident legal entity required for foreign manufacturers; bears post-market vigilance responsibility + JFDA regulatory interface.
• ISO 13485:2016 — recognised by JFDA as QMS evidence framework; Jordanian-specific overlay required including Jordanian quality records + Authorised Representative QMS interface.
• Reliance pathways — JFDA accepts CE Mark + FDA 510(k) + FDA PMA + Health Canada + TGA + Swissmedic + MFDS + Japan-approval evidence as supporting evidence under reliance framework; CE Mark + FDA particularly central.
• GHC Medical Devices Harmonisation — JFDA cooperates with GHC Medical Devices work-streams despite Jordan not being a GCC member; reliance + harmonised technical-file requirements progressively expanding.
• Arab League Medical Devices Harmonisation — JFDA participates in Council of Arab Ministers of Health medical-device harmonisation alongside Egypt EDA + Saudi SFDA + UAE MoHAP + Morocco DMP + Tunisia DPM/ANPM.
• Post-market vigilance — JFDA operates medical-device adverse-event reporting through the Jordanian Matériovigilance System coordinated by JNPC; reporting timelines substantively aligned with IMDRF Adverse Event Reporting Codes.
• IVD Réactovigilance — JFDA operates dedicated IVD réactovigilance reflecting Jordan's substantial clinical-laboratory infrastructure including King Hussein Cancer Center + Jordan University Hospital + King Abdullah University Hospital.
• Cosmetic Notification — cosmetics require JFDA Cosmetic Notification + Arabic + English labelling; INCI-aligned ingredient listing + safety substantiation + cosmétovigilance reporting; substantively EU-aligned framework.
• Food + Dietary Supplement Registration — JFDA Food Directorate operates pre-market food + dietary-supplement registration + post-market food-safety surveillance + HACCP + ISO 22000 + Codex Alimentarius alignment.
• Jordanian UDI — JFDA is progressively implementing UDI requirements substantively aligned with FDA UDI + EU EUDAMED UDI; Jordanian-specific overlay applies.
• Importation Permit — JFDA Importation Permit required in addition to product registration for foreign-manufactured devices + drugs entering Jordan; coordination with Jordan Customs.

JFDA operates the Jordan Pharmacovigilance Programme through the Jordan National Pharmacovigilance Centre (JNPC, Amman). Jordan is a long-standing WHO Programme for International Drug Monitoring (PIDM) member (since 2001) + contributes substantial ADR data to VigiBase via Uppsala Monitoring Centre (UMC). JNPC operates Jordan's integrated pharmacovigilance + matériovigilance + cosmétovigilance centre — an integrated model providing efficient resource use across vigilance functions.

• Jordan National Pharmacovigilance Centre (JNPC, Amman) — integrated pharmacovigilance + matériovigilance + cosmétovigilance centre operating under JFDA Pharmacovigilance Directorate coordination.
• WHO PIDM Long-standing Member — Jordan is a WHO PIDM member since 2001 + contributes substantial ADR data to VigiBase via Uppsala Monitoring Centre.
• Jordan Pharmacovigilance Network — coordinated national pharmacovigilance network with effector centres in major hospitals (Jordan University Hospital, King Hussein Cancer Center, King Abdullah University Hospital, King Hussein Medical Center, Al-Bashir Hospital, Prince Hamzah Hospital) + Royal Medical Services + UNRWA health facilities + Marketing Authorisation Holders.
• Online ADR Reporting — JFDA/JNPC operates online ADR reporting via the JFDA portal + Med Safety App (adopted from Uganda/Kenya/Ethiopia models in 2023); available for healthcare professionals + consumers + Marketing Authorisation Holders.
• E2B(R3) ICSR — JFDA accepts E2B(R3) format ICSR submissions substantively aligned with ICH E2B(R3); 15-day SUSAR reporting timeline for clinical trials + post-market.
• PSUR / PBRER — periodic safety update reports substantively aligned with ICH E2C(R2); JFDA-specific submission timeline.
• Risk Management Plans (RMP) — JFDA requires ICH E2E-aligned Pharmacovigilance Plan + Risk Management Plan for new drugs + biosimilars + vaccines + high-risk products.
• Active surveillance — JFDA/JNPC operates targeted active-surveillance programmes including for HIV antiretrovirals + tuberculosis + COVID-19 vaccines + biologicals + refugee-population pharmacovigilance through UNRWA + UNHCR coordination.
• AEFI Surveillance — Jordanian vaccine adverse-event surveillance aligned with WHO methodology; central to National Immunization Programme + COVID-19 vaccine safety monitoring + refugee-population vaccination programmes.
• Matériovigilance + Réactovigilance + Cosmétovigilance — JFDA/JNPC operates parallel matériovigilance for medical devices + réactovigilance for IVDs + cosmétovigilance for cosmetics.
• Refugee-population pharmacovigilance — distinctive Jordanian model integrating pharmacovigilance for substantial Syrian + Palestinian + Iraqi refugee populations through UNRWA + UNHCR + Jordan Health Aid Society coordination.

• WHO Listed Authority + ML3 — JFDA achieved WHO Maturity Level 3 (ML3) for medicines in 2022 + is a WHO Listed Authority; one of the few Arab-region NRAs at ML3 alongside Saudi SFDA + Egypt EDA.
• WHO PQ CRP Participating Authority — JFDA is an active WHO Prequalification Collaborative Registration Procedure (CRP) participating authority.
• WHO PQ-Lab Since 2011 — JFDA Central Laboratories is one of the earliest WHO PQ-Labs in the Arab World.
• EMA Working Arrangement Since 2018 — JFDA holds an EMA Working Arrangement covering information exchange + reliance + clinical-trial harmonisation + scientific cooperation.
• ANSM France + AEMPS Spain + AIFA Italy + PEI Germany Bilateral — JFDA holds substantial bilateral cooperation with EU national agencies.
• FDA Bilateral — JFDA holds substantial cooperation with FDA reflecting US-Jordan FTA + scientific cooperation + USAID health-systems-strengthening programmes.
• MHRA Bilateral — JFDA holds substantial cooperation with MHRA reflecting historical British-Mandate-era influence + ongoing UK-Jordan health cooperation.
• Health Canada + TGA + Swissmedic Bilateral — JFDA holds bilateral cooperation reflecting Stringent Regulatory Authority reliance practice.
• GHC Cooperation Partner — JFDA cooperates with Gulf Health Council (SFDA + UAE MoHAP + Kuwait MoH + Bahrain NHRA + Oman MoH + Qatar MoPH) despite Jordan not being a GCC member.
• Arab League Council of Arab Ministers of Health Co-leader — JFDA is an active pharmaceutical-harmonisation co-leader alongside Egyptian EDA + Saudi SFDA + Morocco DMP + Tunisia DPM/ANPM + Algeria ANPP + UAE MoHAP + Lebanese MoH + Kuwait MoH + Bahrain NHRA.
• AMRH Arab-region Cooperation Partner — JFDA cooperates with AMRH (African Medicines Regulatory Harmonisation) via Arab League / North African overlap (Egypt EDA + Morocco DMP + Tunisia DPM/ANPM + Algeria ANPP + Libya NRA + Sudan NMPB).
• PIC/S Pre-Accession Applicant — JFDA is on PIC/S Pre-Accession pathway; GMP Guide substantively aligned with PIC/S GMP + EU GMP + ICH Q7.
• ICH Observer — JFDA is an ICH Observer; ICH guidelines extensively implemented in Jordanian regulatory practice including ICH Q7 + Q8 + Q9 + Q10 + Q11 + E2A-E + M4.
• IMDRF Affiliate Candidate — JFDA is positioned for IMDRF Affiliate status + draws on IMDRF guidance for medical-device regulation.
• ICDRA + AVAREF + EMRO participation — active International Conference of Drug Regulatory Authorities + African Vaccine Regulatory Forum + WHO Eastern Mediterranean Regional Office (EMRO) participant.

• Jordanian Authorised Representative not properly designated — application rejected at JFDA intake or post-approval compliance failure.
• Arabic + English labelling deficiencies — Arabic + English labelling required; many applicants provide insufficient Arabic-language patient leaflet or use Modern Standard Arabic without Jordanian dialect considerations.
• JFDA GMP gaps — applicants assuming EU GMP / PIC/S GMP compliance is automatically sufficient without addressing Jordan-specific JFDA GMP clarifications + Jordanian quality records.
• Jordanian climate-zone stability data missing — Jordan spans Climate Zone II (Mediterranean coastal) + Climate Zone IVa (Jordan Valley + Wadi Araba + Aqaba — hot/dry) + selective alpine (Ajloun + northern highlands); applicants frequently provide insufficient zonal-specific stability data particularly for Aqaba + Wadi Araba distribution.
• Bioequivalence centres + biowaiver — JFDA Biowaiver Guidance provides BCS-based biowaivers; applicants frequently submit BE studies where biowaivers would suffice; alternatively many submit insufficient BE evidence where studies are required.
• WHO PQ CRP reliance under-utilised — WHO-PQ-approved products eligible for accelerated JFDA CRP review (90-day target); under-utilised by many applicants.
• EMA Working Arrangement reliance under-utilised — JFDA-EMA Working Arrangement since 2018 provides substantial acceleration for EMA-approved products; under-utilised by many applicants.
• FDA / Health Canada / TGA / Swissmedic reliance under-utilised — JFDA operates substantial reliance on Stringent Regulatory Authority decisions; under-utilised by many applicants.
• GHC reliance not leveraged — Gulf Health Council reliance pathway under-utilised for GHC-assessed products despite Jordan not being a GCC member.
• Arab League harmonisation not leveraged — Council of Arab Ministers of Health pharmaceutical-harmonisation reliance under-utilised for Arab-Reference-Authority-assessed products (Egypt EDA, Saudi SFDA, Morocco DMP, Tunisia DPM/ANPM, UAE MoHAP).
• Essential Medicines accelerated pathway not leveraged — accelerated Marketing Authorisation for Jordanian National Essential Medicines List + refugee-population health priorities under-utilised; 90-120 working day target.
• Veterinary medicines mis-filed — Jordan's distinctive model places veterinary medicines under JFDA (not Ministry of Agriculture as in most Arab countries); foreign veterinary-medicine sponsors frequently mis-file to Ministry of Agriculture.
• Export-orientation considerations — Jordan exports ~80% of domestic pharmaceutical production to ~80 countries; export-orientation strategy considerations frequently overlooked by foreign manufacturers considering Jordan as a manufacturing-hub for MENA + sub-Saharan Africa export.
• Refugee-population pharmacovigilance gaps — distinctive Jordanian model integrating pharmacovigilance for substantial Syrian + Palestinian + Iraqi refugee populations frequently overlooked by Marketing Authorisation Holders.
• Variations strategy not planned — variations procedure substantively similar to EU but with Jordan-specific timelines + fee structure + Arabic/English-language requirements.
• Marketing Authorisation renewal timing missed — 5-year renewal must be filed within prescribed window before expiry; missed deadline triggers de-registration + market withdrawal.
• Clinical trial Higher Council of Science and Technology ethics steps — Jordanian clinical trials require JFDA CTA + Higher Council of Science and Technology ethics approval; sponsors sometimes overlook ethics recognition + multi-site clinical-trial coordination.
• Pharmacovigilance + JNPC gaps — JFDA GVP requirements substantively similar to ICH E2 + EU GVP but with Jordan-specific JNPC integrated vigilance coordination + Arabic + English ICSR.

V5 Ultimate provides the operational infrastructure Jordanian + foreign-supplier sites need for Law 31 of 2003 + Law 41 of 2008 + Law 12 of 2020 + JFDA GMP + JFDA Medical Devices framework + WHO PQ CRP + EMA Working Arrangement + GHC + Arab League + Jordan Pharmacovigilance Programme readiness.

• JFDA GMP control framework — PIC/S + EU GMP + ICH Q7-aligned controls (clean rooms, aseptic process, environmental monitoring, computerised systems) with ALCOA+ data-integrity + Jordan-specific clarifications + Climate Zone II/IVa stability monitoring.
• JFDA Marketing Authorisation dossier packaging — Jordanian CTD-aligned dossier structure with Jordan Module 1 specifics + Module 3 stability + Arabic + English patient leaflet + Authorised Representative declarations + Law 31 of 2003 + Law 12 of 2020 framework.
• WHO PQ CRP workflow — JFDA-as-CRP-participating-authority packaging with reduced dossier + accelerated JFDA review (90-day target).
• EMA Working Arrangement reliance workflow — JFDA-EMA Working Arrangement packaging since 2018 for EMA-approved products.
• FDA / Health Canada / TGA / Swissmedic reliance workflow — Stringent Regulatory Authority reliance packaging.
• GHC workflow — Gulf Health Council cooperation-partner packaging alongside SFDA + UAE MoHAP + Kuwait MoH + Bahrain NHRA + Oman MoH + Qatar MoPH.
• Arab League workflow — Council of Arab Ministers of Health pharmaceutical-harmonisation packaging with Egyptian EDA + Saudi SFDA + Morocco DMP + Tunisia DPM/ANPM + Algeria ANPP + UAE MoHAP coordination.
• Export-orientation workflow — Jordan-as-manufacturing-hub packaging for substantial Jordanian pharmaceutical export market (~80% of domestic production to ~80 countries) supporting MENA + sub-Saharan Africa + Arab World export.
• Essential Medicines accelerated workflow — Jordanian National Essential Medicines List + refugee-population health-priority product packaging with 90-120 working day accelerated review.
• Jordanian Authorised Representative workflow — foreign-manufacturer Authorised Representative designation + role-management + Jordan-specific post-market surveillance + JFDA interface.
• Jordanian clinical-trial workflow — JFDA CTA + Higher Council of Science and Technology ethics + multi-site coordination + Jordanian SUSAR reporting via JNPC.
• JFDA/JNPC Pharmacovigilance integration — E2B(R3) ICSR generation + 15-day SUSAR timeline + PSUR / PBRER packaging + Arabic + English ICSR + Jordan Pharmacovigilance Network coordination + JNPC portal submission + Med Safety App reporting + VigiBase upload + Risk Management Plan packaging + AEFI vaccine adverse-event reporting + refugee-population pharmacovigilance via UNRWA + UNHCR coordination.
• Matériovigilance + Réactovigilance + Cosmétovigilance workflow — parallel matériovigilance + IVD réactovigilance + cosmétovigilance packaging coordinated through JNPC.
• Medical-device + IVD + cosmetic + food + dietary-supplement workflow — Medical Devices Bylaw 32 of 2014 + Food Control Law 79 of 2001 + Cosmetics Bylaw dossier packaging + Class I-III classification + ISO 13485 + Authorised Representative + post-market vigilance.
• Veterinary medicines workflow — distinctive Jordanian model placing veterinary medicines under JFDA (not Ministry of Agriculture) packaging.
• Arab League + GHC + EMA + AMRH regional bridging — for companies operating across MENA + the Arab World + sub-Saharan Africa, V5 surfaces JFDA + Saudi SFDA + UAE MoHAP + Egyptian EDA + Morocco DMP + Tunisia DPM/ANPM + Algeria ANPP + Kuwait MoH + Bahrain NHRA + Oman MoH + Qatar MoPH + Lebanese MoH harmonised dossier-element reuse alongside national-specific extensions.